Dataset Information

Mass spectrometry-based serum biomarker discovery from patients treated with an oncolytic adenovirus encoding TNFα and IL-2 (TILT-123): PROTEOMICS

ABSTRACT: Oncolytic viruses represent an emerging therapeutic approach for treating patients with solid tumours. One such virus, TILT-123 (Ad5/3-E2F-D24-hTNFα-IRES-hIL-2), is a serotype chimeric oncolytic adenovirus. TILT-123 is designed to encode tumour necrosis factor alpha and interleukin-2, aiming to induce T-cell infiltration and cytotoxicity within solid tumours. After several years of preclinical development, TILT-123 is now tested in phase I clinical trials either as a monotherapy, or in combination with other T-cell therapies across various solid tumour types. In a single-arm, multicentre phase I dose-escalation trial TUNIMO (NCT04695327), the safety of TILT-123 in patients with advanced solid cancers refractory to standard therapy was evaluated. During the intravenous phase of the study, researchers collected patient serum to identify potential predictive biomarkers associated with intravenous delivery of TILT-123.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma

SUBMITTER: Sakari Joenväärä

LAB HEAD: Prof. Risto Renkonen

PROVIDER: PXD054594 | Pride | 2026-02-05

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	20240117_TILT_SEC_P_01.raw.zip	Raw
	20240117_TILT_SEC_P_02.raw.zip	Raw
	20240117_TILT_SEC_P_03.raw.zip	Raw
	20240117_TILT_SEC_P_04.raw.zip	Raw
	20240117_TILT_SEC_P_05.raw.zip	Raw

Items per page:

1 - 5 of 71

Similar Datasets

Project description:This model of the use of chimeric antigen receptor (CAR)-T cell therapy in the treatment of solid tumours is described in the article: "Dual-Target CAR-Ts with On- and Off-Tumour Activity May Override Immune Suppression in Solid Cancers: A Mathematical Proof of Concept" Odelaisy León-Triana, Antonio Pérez-Martínez, Manuel Ramírez-Orellana and Víctor M. Pérez-García Cancers 2021, 13, 703.; doi: 10.3390/cancers13040703 Comment: This is the first mathematical model, derived from equations 1 and 2, used in the paper. Reproduction of Fig. 5a was achieved by setting alpha_1 = 0.04, different to the value quoted in the article caption for Fig. 5. Abstract: Chimeric antigen receptor (CAR)-T cell-based therapies have achieved substantial success against B-cell malignancies, which has led to a growing scientific and clinical interest in extending their use to solid cancers. However, results for solid tumours have been limited up to now, in part due to the immunosuppressive tumour microenvironment, which is able to inactivate CAR-T cell clones. In this paper we put forward a mathematical model describing the competition of CAR-T and tumour cells, taking into account their immunosuppressive capacity. Using the mathematical model, we show that the use of large numbers of CAR-T cells targetting the solid tumour antigens could overcome the immunosuppressive potential of cancer. To achieve such high levels of CAR-T cells we propose, and study computationally, the manufacture and injection of CAR-T cells targetting two antigens: CD19 and a tumour-associated antigen. We study in silico the resulting dynamics of the disease after the injection of this product and find that the expansion of the CAR-T cell population in the blood and lymphopoietic organs could lead to the massive production of an army of CAR-T cells targetting the solid tumour, and potentially overcoming its immune suppression capabilities. This strategy could benefit from the combination with PD-1 inhibitors and low tumour loads. Our computational results provide theoretical support for the treatment of different types of solid tumours using T cells engineered with combination treatments of dual CARs with on- and off-tumour activity and anti-PD-1 drugs after completion of classical cytoreductive treatments.

Project description:This model of the use of chimeric antigen receptor (CAR)-T cell therapy in the treatment of solid tumours is described in the article: "Dual-Target CAR-Ts with On- and Off-Tumour Activity May Override Immune Suppression in Solid Cancers: A Mathematical Proof of Concept" Odelaisy León-Triana, Antonio Pérez-Martínez, Manuel Ramírez-Orellana and Víctor M. Pérez-García Cancers 2021, 13, 703.; doi: 10.3390/cancers13040703 Comment: This is the second mathematical model, derived from equations 3 to 6, used in the paper. Reproduction of Figure 5b was achieved by setting alpha_1 = 0.183, in substitution for alpha_1 = 0.2 as quoted in the article. Abstract: Chimeric antigen receptor (CAR)-T cell-based therapies have achieved substantial success against B-cell malignancies, which has led to a growing scientific and clinical interest in extending their use to solid cancers. However, results for solid tumours have been limited up to now, in part due to the immunosuppressive tumour microenvironment, which is able to inactivate CAR-T cell clones. In this paper we put forward a mathematical model describing the competition of CAR-T and tumour cells, taking into account their immunosuppressive capacity. Using the mathematical model, we show that the use of large numbers of CAR-T cells targetting the solid tumour antigens could overcome the immunosuppressive potential of cancer. To achieve such high levels of CAR-T cells we propose, and study computationally, the manufacture and injection of CAR-T cells targetting two antigens: CD19 and a tumour-associated antigen. We study in silico the resulting dynamics of the disease after the injection of this product and find that the expansion of the CAR-T cell population in the blood and lymphopoietic organs could lead to the massive production of an army of CAR-T cells targetting the solid tumour, and potentially overcoming its immune suppression capabilities. This strategy could benefit from the combination with PD-1 inhibitors and low tumour loads. Our computational results provide theoretical support for the treatment of different types of solid tumours using T cells engineered with combination treatments of dual CARs with on- and off-tumour activity and anti-PD-1 drugs after completion of classical cytoreductive treatments.

Dataset Information

Mass spectrometry-based serum biomarker discovery from patients treated with an oncolytic adenovirus encoding TNFα and IL-2 (TILT-123): PROTEOMICS

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets